<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835949</url>
  </required_header>
  <id_info>
    <org_study_id>4309ST101</org_study_id>
    <nct_id>NCT03835949</nct_id>
  </id_info>
  <brief_title>Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, Phase 1 dose escalation study of TJ004309 in combination
      with standard dose atezolizumab in patients with advanced or metastatic cancer in patients
      who are refractory to or intolerant to all available therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerate Dose of TJ004309 plus Atezolizumab</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>Evaluate safety and tolerability and determine a recommended Phase 2 dose of TJ004309 when combined with standard dose atezolizumab in patients with advanced or metastatic cancer. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 and coded using MedDRA 14.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Phase 2 dose to TJ004309 as a single agent</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>Determine the Phase 2 dose of TJ004309 as a single agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough TJ004309 concentrations</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>Trough (pre-dose and post-dose) serum TJ004309 concentrations will be measured when given as a single agent and with atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough atezolizumab concentrations</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>Trough (pre-dose and post-dose) serum atezolizumab concentrations will be measured when given with TJ004309</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Rate of TJ004309 Immunogenicity</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>The number of patients who develop immunogenicity to TJ004309 (anti-product antibody development) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Rate of Atezolizumab Immunogenicity</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>The number of patients who develop immunogenicity to atezolizumab (anti-product antibody development) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of antitumor activity</measure>
    <time_frame>Approximately 2-8 months</time_frame>
    <description>Antitumor activity will be assessed by the response rate by iRECIST and RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>TJ004309 plus Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ004309 will be dose escalated in a 3+3 design in combination with atezolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ004309</intervention_name>
    <description>Antibody to CD73</description>
    <arm_group_label>TJ004309 plus Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Humanized monoclonal antibody to PD-L1</description>
    <arm_group_label>TJ004309 plus Atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed advanced or metastatic cancer in patients who are refractory
             to or intolerant to all available therapy.

          2. Measurable disease by iRECIST

          3. Formalin fixed, paraffin-embedded (FFPE) tumor tissue that permits the preparation of
             12 unstained slides of tumor sample- Biopsy must be excisional, incisional, or core.
             Needle aspiration is insufficient.

          4. Age ≥ 18 years

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          6. Resolution of all acute adverse events resulting from prior cancer therapies to
             National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
             Grade ≤ 1 or baseline (except alopecia or neuropathy)

          7. Adequate organ function

          8. Willingness and ability to consent for self to participate in study

          9. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests, and other study procedures

        Exclusion Criteria:

          1. Autoimmune disease requiring treatment within the past twelve months

          2. Condition requiring systemic treatment with either corticosteroids or other
             immunosuppressive medications within 14 days prior to study treatment

          3. History of or active interstitial lung disease

          4. Prior T-cell or NK cell therapy

          5. Current treatment on another therapeutic clinical trial

          6. Receipt of systemic anticancer therapy, including investigational agents, within 28
             days prior to study treatment

          7. Major surgical procedure or significant traumatic injury within 4 weeks prior to study
             treatment, and must have fully recovered from any such procedure; and no date of
             surgery (if applicable) or anticipated need for a major surgical procedure planned
             within the next 6 months

          8. Chest radiotherapy ≤ 28 days, wide field radiotherapy ≤ 28 days (defined as &gt; 50% of
             volume of pelvic bones or equivalent), or limited field radiation for palliation ≤ 14
             days prior to study treatment - such patients must have recovered adequately from any
             side effects of such therapy.

          9. Hypertension defined as blood pressure (BP) systolic &gt; 150 or diastolic &gt; 90 mm Hg

         10. Ascites or pericardial effusion that required intervention within 3 months prior to
             study treatment.

         11. Brain involvement with cancer, spinal cord compression, or carcinomatous meningitis,
             or new evidence of brain or leptomeningeal disease, unless the lesion(s) have been
             radiated or resected, are considered fully treated and inactive, are asymptomatic, and
             no steroids have been administered for CNS disease over the 7 days prior to study
             treatment

         12. Angina, myocardial infarction (MI), symptomatic congestive heart failure,
             cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary
             embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery
             bypass grafting (CABG) within 6 months prior to study treatment

         13. Thrombolytic use (except to maintain IV catheters) within 10 days prior study
             treatment

         14. Known active viral or nonviral hepatitis or cirrhosis, except patients with Hepatitis
             C infection and undetectable virus following treatment are eligible.

         15. Any active infection requiring systemic treatment

         16. History of hemorrhage or hemoptysis (&gt; ½ teaspoon bright red blood) within 3 months
             prior to study treatment

         17. Known human immunodeficiency virus (HIV) unless CD4+ T cell count &gt; 350 cells/μL with
             an undetectable viral load.

         18. Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥ 6
             weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal
             ligation) or be postmenopausal for at least one year, or must agree to use effective
             contraception during the study and for 5 months following last dose of TJ004309. All
             female patients of reproductive potential must have a negative pregnancy test (serum
             or urine) within 7 days prior to study treatment. Male patients must be surgically
             sterile or must agree to use effective contraception during the study and for 5 months
             following last dose of TJ004309.

         19. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or may
             interfere with the interpretation of study results and, in the judgment of the
             Investigator, would make the patient inappropriate for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Theuer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Theuer, MD, PhD</last_name>
    <phone>(858) 251-3490</phone>
    <email>clinicaltrials@traconpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.traconpharma.com</url>
    <description>TRACON Pharmaceuticals</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

